Selected research
Market Analysis & Forecast
Global Cell therapy platform Market Analysis and Forecast 2026-2032
Market perspective
The global Cell therapy platform market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Cell therapy platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Cell therapy platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Cell therapy platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Cell therapy platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Cell therapy platform include Novartis, Gilead Sciences, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Roche, Bluebird Bio, Cellectis, Sangamo Therapeutics and Fate Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Cell therapy platform, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Cell therapy platform, also provides the revenue of main regions and countries. Of the upcoming market potential for Cell therapy platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cell therapy platform revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell therapy platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell therapy platform revenue, projected growth trends, production technology, application and end-user industry.
Cell therapy platform Segment by Company
Novartis
Gilead Sciences
Regeneron Pharmaceuticals
Takeda Pharmaceuticals
Roche
Bluebird Bio
Cellectis
Sangamo Therapeutics
Fate Therapeutics
Cell therapy platform Segment by Type
Autologous Cell Therapy Platform
Allogeneic Cell Therapy Platform
Others
Cell therapy platform Segment by Application
General Hospital
Specialized Hospital
Others
Cell therapy platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell therapy platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell therapy platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell therapy platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Cell therapy platform in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Cell therapy platform company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell therapy platform revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Cell Therapy Platform
- Allogeneic Cell Therapy Platform
- Others
Applications
- General Hospital
- Specialized Hospital
- Others
Companies covered
- Novartis
- Gilead Sciences
- Regeneron Pharmaceuticals
- Takeda Pharmaceuticals
- Roche
- Bluebird Bio
- Cellectis
- Sangamo Therapeutics
- Fate Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Cell therapy platform Market by Type
- 1.2.1 Global Cell therapy platform Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Autologous Cell Therapy Platform
- 1.2.3 Allogeneic Cell Therapy Platform
- 1.2.4 Others
- 1.3 Cell therapy platform Market by Application
- 1.3.1 Global Cell therapy platform Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 General Hospital
- 1.3.3 Specialized Hospital
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cell therapy platform Market Dynamics
- 2.1 Cell therapy platform Industry Trends
- 2.2 Cell therapy platform Industry Drivers
- 2.3 Cell therapy platform Industry Opportunities and Challenges
- 2.4 Cell therapy platform Industry Restraints
3 Global Growth Perspective
- 3.1 Global Cell therapy platform Market Perspective (2021-2032)
- 3.2 Global Cell therapy platform Growth Trends by Region
- 3.2.1 Global Cell therapy platform Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Cell therapy platform Market Size by Region (2021-2026)
- 3.2.3 Global Cell therapy platform Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Cell therapy platform Revenue by Players
- 4.1.1 Global Cell therapy platform Revenue by Players (2021-2026)
- 4.1.2 Global Cell therapy platform Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Cell therapy platform Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Cell therapy platform Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Cell therapy platform Key Players Headquarters & Area Served
- 4.4 Global Cell therapy platform Players, Product Type & Application
- 4.5 Global Cell therapy platform Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Cell therapy platform Market CR5 and HHI
- 4.6.3 2025 Cell therapy platform Tier 1, Tier 2, and Tier 3
5 Cell therapy platform Market Size by Type
- 5.1 Global Cell therapy platform Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Cell therapy platform Revenue by Type (2021-2032)
- 5.3 Global Cell therapy platform Revenue Market Share by Type (2021-2032)
6 Cell therapy platform Market Size by Application
- 6.1 Global Cell therapy platform Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Cell therapy platform Revenue by Application (2021-2032)
- 6.3 Global Cell therapy platform Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Novartis
- 7.1.1 Novartis Company Information
- 7.1.2 Novartis Business Overview
- 7.1.3 Novartis Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.1.4 Novartis Cell therapy platform Product Portfolio
- 7.1.5 Novartis Recent Developments
- 7.2 Gilead Sciences
- 7.2.1 Gilead Sciences Company Information
- 7.2.2 Gilead Sciences Business Overview
- 7.2.3 Gilead Sciences Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.2.4 Gilead Sciences Cell therapy platform Product Portfolio
- 7.2.5 Gilead Sciences Recent Developments
- 7.3 Regeneron Pharmaceuticals
- 7.3.1 Regeneron Pharmaceuticals Company Information
- 7.3.2 Regeneron Pharmaceuticals Business Overview
- 7.3.3 Regeneron Pharmaceuticals Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.3.4 Regeneron Pharmaceuticals Cell therapy platform Product Portfolio
- 7.3.5 Regeneron Pharmaceuticals Recent Developments
- 7.4 Takeda Pharmaceuticals
- 7.4.1 Takeda Pharmaceuticals Company Information
- 7.4.2 Takeda Pharmaceuticals Business Overview
- 7.4.3 Takeda Pharmaceuticals Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.4.4 Takeda Pharmaceuticals Cell therapy platform Product Portfolio
- 7.4.5 Takeda Pharmaceuticals Recent Developments
- 7.5 Roche
- 7.5.1 Roche Company Information
- 7.5.2 Roche Business Overview
- 7.5.3 Roche Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.5.4 Roche Cell therapy platform Product Portfolio
- 7.5.5 Roche Recent Developments
- 7.6 Bluebird Bio
- 7.6.1 Bluebird Bio Company Information
- 7.6.2 Bluebird Bio Business Overview
- 7.6.3 Bluebird Bio Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.6.4 Bluebird Bio Cell therapy platform Product Portfolio
- 7.6.5 Bluebird Bio Recent Developments
- 7.7 Cellectis
- 7.7.1 Cellectis Company Information
- 7.7.2 Cellectis Business Overview
- 7.7.3 Cellectis Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.7.4 Cellectis Cell therapy platform Product Portfolio
- 7.7.5 Cellectis Recent Developments
- 7.8 Sangamo Therapeutics
- 7.8.1 Sangamo Therapeutics Company Information
- 7.8.2 Sangamo Therapeutics Business Overview
- 7.8.3 Sangamo Therapeutics Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.8.4 Sangamo Therapeutics Cell therapy platform Product Portfolio
- 7.8.5 Sangamo Therapeutics Recent Developments
- 7.9 Fate Therapeutics
- 7.9.1 Fate Therapeutics Company Information
- 7.9.2 Fate Therapeutics Business Overview
- 7.9.3 Fate Therapeutics Cell therapy platform Revenue and Gross Margin (2021-2026)
- 7.9.4 Fate Therapeutics Cell therapy platform Product Portfolio
- 7.9.5 Fate Therapeutics Recent Developments
8 North America
- 8.1 North America Cell therapy platform Revenue (2021-2032)
- 8.2 North America Cell therapy platform Revenue by Type (2021-2032)
- 8.2.1 North America Cell therapy platform Revenue by Type (2021-2026)
- 8.2.2 North America Cell therapy platform Revenue by Type (2027-2032)
- 8.3 North America Cell therapy platform Revenue Share by Type (2021-2032)
- 8.4 North America Cell therapy platform Revenue by Application (2021-2032)
- 8.4.1 North America Cell therapy platform Revenue by Application (2021-2026)
- 8.4.2 North America Cell therapy platform Revenue by Application (2027-2032)
- 8.5 North America Cell therapy platform Revenue Share by Application (2021-2032)
- 8.6 North America Cell therapy platform Revenue by Country
- 8.6.1 North America Cell therapy platform Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Cell therapy platform Revenue by Country (2021-2026)
- 8.6.3 North America Cell therapy platform Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Cell therapy platform Revenue (2021-2032)
- 9.2 Europe Cell therapy platform Revenue by Type (2021-2032)
- 9.2.1 Europe Cell therapy platform Revenue by Type (2021-2026)
- 9.2.2 Europe Cell therapy platform Revenue by Type (2027-2032)
- 9.3 Europe Cell therapy platform Revenue Share by Type (2021-2032)
- 9.4 Europe Cell therapy platform Revenue by Application (2021-2032)
- 9.4.1 Europe Cell therapy platform Revenue by Application (2021-2026)
- 9.4.2 Europe Cell therapy platform Revenue by Application (2027-2032)
- 9.5 Europe Cell therapy platform Revenue Share by Application (2021-2032)
- 9.6 Europe Cell therapy platform Revenue by Country
- 9.6.1 Europe Cell therapy platform Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Cell therapy platform Revenue by Country (2021-2026)
- 9.6.3 Europe Cell therapy platform Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Cell therapy platform Revenue (2021-2032)
- 10.2 China Cell therapy platform Revenue by Type (2021-2032)
- 10.2.1 China Cell therapy platform Revenue by Type (2021-2026)
- 10.2.2 China Cell therapy platform Revenue by Type (2027-2032)
- 10.3 China Cell therapy platform Revenue Share by Type (2021-2032)
- 10.4 China Cell therapy platform Revenue by Application (2021-2032)
- 10.4.1 China Cell therapy platform Revenue by Application (2021-2026)
- 10.4.2 China Cell therapy platform Revenue by Application (2027-2032)
- 10.5 China Cell therapy platform Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Cell therapy platform Revenue (2021-2032)
- 11.2 Asia Cell therapy platform Revenue by Type (2021-2032)
- 11.2.1 Asia Cell therapy platform Revenue by Type (2021-2026)
- 11.2.2 Asia Cell therapy platform Revenue by Type (2027-2032)
- 11.3 Asia Cell therapy platform Revenue Share by Type (2021-2032)
- 11.4 Asia Cell therapy platform Revenue by Application (2021-2032)
- 11.4.1 Asia Cell therapy platform Revenue by Application (2021-2026)
- 11.4.2 Asia Cell therapy platform Revenue by Application (2027-2032)
- 11.5 Asia Cell therapy platform Revenue Share by Application (2021-2032)
- 11.6 Asia Cell therapy platform Revenue by Country
- 11.6.1 Asia Cell therapy platform Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Cell therapy platform Revenue by Country (2021-2026)
- 11.6.3 Asia Cell therapy platform Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Cell therapy platform Revenue (2021-2032)
- 12.2 SAMEA Cell therapy platform Revenue by Type (2021-2032)
- 12.2.1 SAMEA Cell therapy platform Revenue by Type (2021-2026)
- 12.2.2 SAMEA Cell therapy platform Revenue by Type (2027-2032)
- 12.3 SAMEA Cell therapy platform Revenue Share by Type (2021-2032)
- 12.4 SAMEA Cell therapy platform Revenue by Application (2021-2032)
- 12.4.1 SAMEA Cell therapy platform Revenue by Application (2021-2026)
- 12.4.2 SAMEA Cell therapy platform Revenue by Application (2027-2032)
- 12.5 SAMEA Cell therapy platform Revenue Share by Application (2021-2032)
- 12.6 SAMEA Cell therapy platform Revenue by Country
- 12.6.1 SAMEA Cell therapy platform Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Cell therapy platform Revenue by Country (2021-2026)
- 12.6.3 SAMEA Cell therapy platform Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst